Adalimumab sustains improvement in spinal mobility in as patients through 104 weeks - Results from atlas
Príomhchruthaitheoirí: | Wordsworth, P, Dijkmans, B, van der Heijde, D, Davis, J, Schiff, M, Kivitz, A, Sieper, J, Mease, P, Kupper, H, Wong, R, Grp, A |
---|---|
Formáid: | Conference item |
Foilsithe / Cruthaithe: |
2008
|
Míreanna comhchosúla
Míreanna comhchosúla
-
CLINICAL RESPONSE AND PARTIAL REMISSION SUSTAINED THROUGH 3 YEARS OF ADALIMUMAB TREATMENT IN THE ATLAS TRIAL
de réir: Wordsworth, P, et al.
Foilsithe / Cruthaithe: (2009) -
Treatment with adalimumab reduces signs and symptoms and induces partial remission in patients with ankylosing spondylitis (AS): 1-year results from ATLAS.
de réir: van der Heijde, D, et al.
Foilsithe / Cruthaithe: (2006) -
Maintenance of reduction in disease activity and partial remission in patients with Ankylosing spondylitis (AS) - 3-year results from the adalimumab (HUMIRO) trial evaluating long-term efficacy and safety in AS (ATLAS)
de réir: van der Heijde, D, et al.
Foilsithe / Cruthaithe: (2008) -
Adalimumab improves health-related quality of life in patients with active ankylosing spondylitis - The ATLAS trial.
de réir: Van der Heijde, D, et al.
Foilsithe / Cruthaithe: (2005) -
Adalimumab enhances health-related quality of life in patients with active ankylosing spondylitis - Results from the atlas trial
de réir: van der Heijde, D, et al.
Foilsithe / Cruthaithe: (2006)